Lakefront Biotherapeutics (formerly Galapagos NV, ticker LKFT) is a clinical-stage biotechnology company focused on building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The company's portfolio is anchored by gamgertamig, a BCMAxCD3 T-cell engager being developed in collaboration with Gilead Sciences for autoimmune diseases including autoimmune hemolytic anemia, immune thrombocytopenia, idiopathic inflammatory myositis, Sjögren's disease, and pemphigus. Lakefront acquired substantially all of Ouro Medicines' operational assets and team in June 2026, and also in-licensed three preclinical autoimmune and inflammatory disease programs from Ouro. The company previously developed Jyseleca (filgotinib), a JAK1 inhibitor for rheumatoid arthritis and ulcerative colitis, which was transferred to Alfasigma in early 2024. Lakefront retains royalty streams and contingent consideration from Alfasigma related to Jyseleca. The company is winding down its oncology CAR-T cell therapy activities. Lakefront also has a TYK2 inhibitor program (GLPG3667) with completed Phase 2 studies in dermatomyositis and SLE, for which strategic options are being evaluated. Additionally, the company holds a 29.12% equity stake in Coultreon Biopharma, which is developing COL-5671 (a SIK3 inhibitor originally developed by Lakefront). Listed on Euronext Amsterdam/Brussels and NASDAQ, the company maintains a strong cash and financial investments position of approximately €2.2 billion and operates a capital deployment strategy combining clinical development, business development, and disciplined capital allocation through its strategic relationship with Gilead Sciences. Updated
Wednesday's top analyst upgrades and downgrades included Alphabet, Facebook, Harley-Davidson, JetBlue Airways, Lowe's Companies, Occidental Petroleum, Overstock.com, Snap and Southwest Airlines.
Tuesday's top analyst upgrades and downgrades included Advance Auto Parts, Dish Network, Intuit, Kroger, Palo Alto Networks, Qorvo, Starbucks and Texas Instruments.
Galapagos was crushed on Wednesday after the firm, in conjunction with Gilead, announced a new commercialization and development agreement for their Rheumatoid Arthritis (RA) treatment.
Tuesday's top analyst upgrades and downgrades included Crocs, Gap, GW Pharmaceuticals, Lowe's Companies, Merck, Nio, Palo Alto Networks, Phillips 66, Starbucks and Vital Farms.
The FDA has come down on an investigational treatment for moderately to severely active from Gilead Sciences and Galapagos.
Monday's top analyst upgrades, downgrades and initiations included Agilent Technologies, Antero Midstream, Chewy, Domino's Pizza, eHealth, First Solar, Kraft Heinz, Newmont, Square, Tilray and Wayfair.
Thursday's top analyst upgrades, downgrades and initiations included Advanced Micro Devices, American Electric Power, Analog Devices, CenturyLink, Dish Network, Herbalife, NextEra Energy, NRG Energy, On Semiconductor and SolarEdge Technologies.
Monday's top analyst upgrades, downgrades and initiations included Alphabet, Apple, Bank of America, Citigroup, Dollar Tree, Nordstrom, Salesforce, Travelers and JD.com.
Lakefront Biotherapeutics (formerly Galapagos NV, ticker LKFT) is a clinical-stage biotechnology company focused on building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.
